Astellas Signs Agreement With NeurogesX For Qutenza
This article was originally published in PharmAsia News
Executive Summary
Astellas June 23 signed a licensing agreement with U.S. biotech NeurogesX and obtained exclusive rights to distribute, develop and market Qutenza in Europe, the Middle East and Africa. Astellas subsidiary Astellas Europe will pay 30 million euros in a one-time payment and will pay 5 million euros for the option to co-develop and co-market NGX-1998. Qutenza is an agent to relieve pain associated with peripheral neuropathic pain conditions. It obtained an approval from the European Medicines Agency for non-diabetic pain relief this May. (Click here for more - Japanese language
You may also be interested in...
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.